A Diagnostic Challenge: Hepatitis C Virus (HCV)-Associated Membranoproliferative Glomerulonephritis in the Setting of Multiple Comorbidities (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0731; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "The nephrology team considered plasmapheresis and rituximab; however, due to transiently resolving cryoglobulins of unclear etiology, potential removal of antiviral medications, and concerns for hepatitis B reactivation in the setting of questionable medication compliance, both treatments were not pursued. The patient was ultimately treated with prednisone (~1mg/kg followed by a taper over 4 weeks), Entecavir, Epclusa, and discharged from the hospital...Discussion MPGN is often driven by underlying immune complex or complement dysregulation, with infections such as hepatitis B and C being important treatable causes. Thorough evaluation for etiology is necessary, since management strategies differ and inappropriate treatment may worsen outcomes."
Complement-mediated Rare Disorders • Glomerulonephritis • Hematological Malignancies • Hepatitis B • Hepatitis C • Hepatology • Hypertension • Immunology • Indolent Lymphoma • Infectious Disease • Inflammation • Lupus Nephritis • Lymphoma • Nephrology • Renal Disease
|
|
Addie Flowers; Jackeline Flores; Piruthiviraj Natarajan; Leo Yamaguchi
|